C07K 16/3023
Lung
Official title: {Lung}
C07K16/3023 (Lung) appears on 569 US grants and 920 published applications in this corpus.
Search patents in C07K- Granted patents
- 569
- Published applications
- 920
- Assignees
- 289
- Inventors
- 1,308
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 3 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 5 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 0 |
| 2002 | 1 | 12 |
| 2003 | 2 | 147 |
| 2004 | 3 | 10 |
| 2005 | 4 | 16 |
| 2006 | 6 | 16 |
| 2007 | 58 | 13 |
| 2008 | 30 | 14 |
| 2009 | 8 | 25 |
| 2010 | 11 | 14 |
| 2011 | 9 | 16 |
| 2012 | 4 | 17 |
| 2013 | 11 | 18 |
| 2014 | 16 | 41 |
| 2015 | 27 | 45 |
| 2016 | 47 | 95 |
| 2017 | 34 | 104 |
| 2018 | 60 | 55 |
| 2019 | 45 | 55 |
| 2020 | 45 | 42 |
| 2021 | 30 | 42 |
| 2022 | 23 | 37 |
| 2023 | 20 | 21 |
| 2024 | 14 | 28 |
| 2025 | 13 | 20 |
| 2026 | 7 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-DLL3 antibodies and methods of use21 Jul 2026US 12,686,725 B2Mythic Therapeutics, Inc.
- Antigen-binding proteins and related methods of use19 May 2026US 12,630,637 B2Gritstone Bio, Inc.
- Compositions and methods for the diagnosis and treatment of tumor24 Mar 2026US 12,583,937 B2Genentech, Inc.
- CEACAM5 antibody-drug conjugate formulation3 Mar 2026US 12,564,642 B2Sanofi
- Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof10 Feb 2026US 12,545,735 B2Regeneron Pharmaceuticals, Inc.
- Anti-dll3 antibodies and methods of use1 Oct 2026US 2026/0297212 A1Mythic Therapeutics, Inc.
- Lung cancer targeting human antibodies and therapeutic uses thereof27 Aug 2026US 2026/0250413 A1Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - Irst S.R.L.
- Anti-vista antibodies and fragments13 Aug 2026US 2026/0234264 A1Janssen Pharmaceutica NV
- Antibody-drug conjugates against the receptor tyrosine kinase epha530 Jul 2026US 2026/0216365 A1MBrace Therapeutics, Inc.
- Anti-mesothelin nanobody chimeric antigen receptor and use thereof9 Jul 2026US 2026/0191958 A1Shanghai Cell Therapy Group Co., Ltd.
Most cited
By later US patents
- Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents147US 7,303,749 B1ImmunoGen, Inc. · 2007
- Genetic products differentially expressed in tumors and the use thereof105US 7,527,933 B2Ganymed Pharmaceuticals AG · 2009
- Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes92US 4,954,617 ATrustees of Dartmouth College · 1990
- Modified/chimeric superantigens and their use72US 6,514,498 B1Pharmacia Corporation · 2003
- Antibodies specific for Trop-2 and their uses72US 8,871,908 B2Rinat Neuroscience Corp. · 2014